Nivolumab,Ipilimumab,Sunitinib
BMS,Pfizer
[]
important analyses from chrckmate-214 presented by at #asco23. there are clearly signals of efficacy here as well - it will be important to more fully identify the subset of patients who will benefit from adjuvant io 
Oncologist, physician-scientist, Assistant Professor @YaleCancer @YaleMed | cancer immunotherapy, genomics, kidney cancer | tweets ≠ medical advice.